The Effects of Exercise in Parkinson's Disease

Parkinson Disease 10 Clinical Trial

— PET  

Official title:

The Effects of Exercise in Parkinson's Disease.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01835652
• Other study ID #: H13-00276
• Status: Completed
• Phase: N/A
• Start date: April 2013
• Est. completion date: March 2015

Study information

• Verified date: March 2021
• Source: Pacific Parkinson's Research Centre
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Parkinson's disease is caused by a reduction of dopamine causing motor deficits. The investigators are studying how exercise can help PD patients by increasing dopamine release in an area of the brain that coordinates movement, the striatum. The investigators will enroll PD patients into two groups; one group will complete a 12-week aerobic exercise program and the other will complete a 12-week control program including yoga and stretching only. The investigators will measure changes in dopamine release before and after either 12-week intervention. Subjects will complete motor and cognitive questionnaires in addition to functional magnetic resonance imaging and positron emission tomography neuroimaging.

Description:

The purpose of this study is to determine the basis for symptomatic and disease modifying benefits of exercise in Parkinson's disease (PD). Although the benefits of exercise in PD have been purported for several decades, only recently have there been controlled reports of symptomatic benefits in Parkinson's disease in terms of bradykinesia, postural balance and quality of life. There have been unsubstantiated suggestions that exercise may improve cognition and mood in PD. The mechanisms underlying such benefits are poorly understood. Exercise may induce dopamine release, thereby contributing to improved motor function in the dorsal striatum, and to enhanced mood and reduced apathy in the ventral striatum. We will test the hypotheses that exercise results in altered synaptic plasticity in the form of altered connectivity in response to aerobic exercise and reward-induced dopamine release. We will assess networks of functional connectivity using functional magnetic resonance imaging and measure dopamine release with positron emission tomography (PET).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: March 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Idiopathic PD according to UK Brain Bank criteria (modified to permit inclusion of subjects with a family history)

2. Ages 40-70

3. Mild to moderate Parkinsonism (Hoehn & Yahr stages I-III) Exclusion Criteria:

General exclusion criteria will include:

1. more than 120 minutes per week of activities >3 MET or a score exceeding 4 on the "Baseline Exercise Screening Tool" (Appendix, Fig. 1);

2. atypical Parkinson syndrome (progressive supranuclear palsy, multiple system atrophy, drug-induced etc.);

3. significant osteoporosis or arthritis;

4. other neurological disease (e.g. myopathy);

5. self-reports claustrophobia;

6. history of cancer within 5 years of study participation;

7. high dose of radiation from other procedures within the year;

8. taking rasagiline or selegiline for PD therapy;

9. diabetic;

10. not able to tolerate being off PD medication for up to 24 hours;

11. BMI of 35 or more; and

12. a female subject who is breast-feeding or pregnant.

Exclusion criteria for MRI scanning and magnetic stimulation from rTMS scanning includes:

1. artificial heart valve;

2. brain aneurysm clip;

3. electrical stimulator for nerves or bones;

4. ear or eye implant;

5. implanted drug infusion pump;

6. coil, catheter, or filter in any blood vessel;

7. orthopedic hardware (artificial joint, plate, screws);

8. other metallic prostheses;

9. shrapnel, bullets, or other metal fragments;

10. surgery or tattoos (including tattooed eyeliner) in the last six weeks;

11. have a cardiac pacemaker, wires or defibrillator;

12. have had an injury where a piece of metal lodged in your eye or orbit;

13. have a ferromagnetic aneurysm clip; and

14. have a history of seizures. Subjects may be excluded following study enrollment if they meet any of the following

exclusion criteria:

1. significant cognitive impairment (Montreal Cognitive Assessment score < 24) or depression (Beck Depression Inventory score > 18);

2. significant or unstable cardiovascular or respiratory disease - all subjects will undergo a screening exercise bicycle stress test; or

3. failure to comply with the exercise or yoga/stretching intervention program, including missing 5 sessions or missing three sessions in a row.

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson Disease 10

Intervention

Other:
• Active Exercise

• Passive Exercise

Locations

Country	Name	City	State
Canada	Pacific Parkinson's Research Centre	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Pacific Parkinson's Research Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Clinical Measures	Motor function will be assessed using the MDS-Unified Parkinson's Disease Rating Scale, finger tapping and Purdue Pegboard. Cognitive function will be assessed using the Montreal Cognitive Assessment, Wisconsin Card-Sorting Task, Trail-Making B Test and a computerized reaction time test. Mood and apathy will be assessed using the Beck Depression Inventory and Starkstein Apathy Scale.	3 months
Primary	PET	Dopamine release will be assessed using positron emission tomography (PET)	3 months
Secondary	fMRI	fMRI will be performed to record response to rewarding stimuli	3 months